1. |
- Abazov, V. M., et al.
(author)
-
The upgraded DO detector
- 2006
-
In: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 565:2, s. 463-537
-
Journal article (peer-reviewed)abstract
- The DO experiment enjoyed a very successful data-collection run at the Fermilab Tevatron collider between 1992 and 1996. Since then, the detector has been upgraded to take advantage of improvements to the Tevatron and to enhance its physics capabilities. We describe the new elements of the detector, including the silicon microstrip tracker, central fiber tracker, solenoidal magnet, preshower detectors, forward muon detector, and forward proton detector. The uranium/liquid -argon calorimeters and central muon detector, remaining from Run 1, are discussed briefly. We also present the associated electronics, triggering, and data acquisition systems, along with the design and implementation of software specific to DO.
|
|
2. |
- Abazov, V. M., et al.
(author)
-
Measurement of the isolated photon cross section in p(p)over-bar collisions at root s=1.96 TeV
- 2006
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 639:3-4, s. 151-158
-
Journal article (peer-reviewed)abstract
- The cross section for the inclusive production of isolated photons has been measured in p (p) over bar collisions at root s = 1.96 TeV with the DO detector at the Fermilab Tevatron Collider. The photons span transverse momenta 23 to 300 GeV and have pseudorapidity vertical bar n vertical bar < 0.9. The cross section is compared with the results from two next-to-leading order perturbative QCD calculations. The theoretical predictions agree with the measurement within uncertainties.
|
|
3. |
|
|
4. |
- Strandberg, Linn S
(author)
-
Ro52 antibodies and susceptibility genes in congenital heart block
- 2007
-
Doctoral thesis (other academic/artistic)abstract
- Congenital heart block (CHB) develops in fetuses of Ro/SSA and La/SSB positive women. During pregnancy, the autoantibodies cross the placenta and affect the fetus in which a potentially lethal atrioventricular (AV) block may develop. This thesis is aimed at identifying clinically useful maternal serologic markers predictive of risk for CHB, and to define genes linked to susceptibility in the child. Ro52-p200 antibodies, binding amino acid 200-239 of the Ro52 protein, was recently suggested by our group as a marker for high risk pregnancies. Performing a multinational study we now show that p200 antibodies are highly relevant as a second step analysis in Ro52-positive pregnancies, and increase the positive predictive value for fetal cardiac involvement. The incidence of CHB in Ro/La positive women is 1-2%. This risk is only increased to 20% in subsequent pregnancies despite persisting antibodies, indicating that there are other factors involved in disease susceptibility than antibody specificity alone. Ro/La antibody levels and Ro52 subclass profiles were investigated longitudinally through pregnancies and revealed no significant differences between affected and healthy pregnancy outcomes. There were no significant decreases or peaks in antibody levels corresponding to or preceding the time point when CHB is usually detected. We therefore investigated differences in fetal susceptibility to CHB. Fetal genetic factors in susceptibility to CHB have been suggested, but not previously investigated experimentally, To investigate MHC and non-MHC associations of the disease, an immunization model of CHB was established in rat. Analysis of MHC and non-MHC genetic influences using congenic rat strains and an F2 cross revealed significant associations with MHC encoded genes. Maternal generation of pathogenic antibody specificity was linked to a specific MHC haplotype, whereas fetal susceptibility to development of CHB was linked to a separate MHC haplotype in the fetus. Patterns of inheritance also indicated a possible epigenetic influence in susceptibility to CHB. Our data suggest complex genetic prerequisites for susceptibility, and explain why simple associations with MHC genes have not been observed in human studies of CHB. The cellular function of the Ro52 autoantigen was also investigated. We show that Ro52 is an E3 ubiquitin ligase and using a panel of Ro52 monoclonal antibodies which was generated, we show that R52 locates predominantly to the cytoplasm. Stimulation of cells with the systemic autoimmune-related cytokine IFN-alpha induced translocation of Ro52 from the cytoplasm to the nucleus, which preceded apoptosis of the cells. In summary, we identify Ro52-p200 antibodies as a clinically useful marker for risk of CHB and show that fetal susceptibility to these pathogenic autoantibodies depend on fetal MHC-encoded genes. We also demonstrate that Ro52 is an E3 ligase, and that cytokines involved in systemic autoimmunity regulate the cellular localization of the Ro52 autoantigen.
|
|
5. |
- Strandberg, Ragnhild B., et al.
(author)
-
Gestational diabetes mellitus by maternal country of birth and length of residence in immigrant women in Norway
- 2021
-
In: Diabetic Medicine. - : John Wiley & Sons. - 0742-3071 .- 1464-5491. ; 38:6
-
Journal article (peer-reviewed)abstract
- Aims: Immigrant women are at higher risk for gestational diabetes mellitus (GDM) than non-immigrant women. This study described the prevalence of GDM in immigrant women by maternal country of birth and examined the associations between immigrants' length of residence in Norway and GDM.Methods: This Norwegian national population-based study included 192,892 pregnancies to immigrant and 1,116,954 pregnancies to non-immigrant women giving birth during the period 1990-2013. Associations were reported as odds ratios (ORs) with 95% confidence intervals (CIs) using logistic regression models, adjusted for year of delivery, maternal age, marital status, health region, parity, education and income.Results: The prevalence and adjusted OR [CI] for GDM were substantially higher in immigrant women from Bangladesh (7.4%, OR 8.38 [5.41, 12.97]), Sri Lanka (6.3%, OR 7.60 [6.71, 8.60]), Pakistan (4.3%, OR 5.47 [4.90, 6.11]), India (4.4%, OR 5.18 [4.30, 6.24]) and Morocco (4.3%, OR 4.35 [3.63, 5.20]) compared to non-immigrants (prevalence 0.8%). Overall, GDM prevalence increased from 1.3% (OR 1.25 [1.14, 1.36]) to 3.3% (OR 2.55 [2.39, 2.71]) after 9 years of residence in immigrants compared to non-immigrant women. This association was particularly strong for women from South Asia.Conclusions: Gestational diabetes mellitus prevalence varied substantially between countries of maternal birth and was particularly high in immigrants from Asian countries. GDM appeared to increase with longer length of residence in certain immigrant groups.
|
|
6. |
- Uhlén, Mathias, et al.
(author)
-
The human secretome
- 2019
-
In: Science Signaling. - : American Association for the Advancement of Science (AAAS). - 1945-0877 .- 1937-9145. ; 12:609
-
Journal article (peer-reviewed)abstract
- The proteins secreted by human cells (collectively referred to as the secretome) are important not only for the basic understanding of human biology but also for the identification of potential targets for future diagnostics and therapies. Here, we present a comprehensive analysis of proteins predicted to be secreted in human cells, which provides information about their final localization in the human body, including the proteins actively secreted to peripheral blood. The analysis suggests that a large number of the proteins of the secretome are not secreted out of the cell, but instead are retained intracellularly, whereas another large group of proteins were identified that are predicted to be retained locally at the tissue of expression and not secreted into the blood. Proteins detected in the human blood by mass spectrometry-based proteomics and antibody-based immuno-assays are also presented with estimates of their concentrations in the blood. The results are presented in an updated version 19 of the Human Protein Atlas in which each gene encoding a secretome protein is annotated to provide an open-access knowledge resource of the human secretome, including body-wide expression data, spatial localization data down to the single-cell and subcellular levels, and data about the presence of proteins that are detectable in the blood.
|
|